arrow
T

Tomoki� Ito

Kansai Medical University
H指数:41
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis (JUL, 10.1007/s00277-024-05898-3, 2024)
2024-08-210
OA
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients
2024-08-210
PRE
Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis
2024-07-221
PRE
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

daratumumab后elotuzumab治疗多发性骨髓瘤的疗效恶化: 一项多中心回顾性研究

2024-03-161
PRE
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)

日本多发性骨髓瘤患者每周一次卡非佐米的观察性研究 (每周CAR研究)

2024-02-290
OAAI
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
2023-03-295
OAAI
Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide
2022-12-132
OAAI
Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation

具有临床危险因素的患者早期血浆生物标志物升高可预测异基因造血干细胞移植后非复发死亡率增加

2021-08-016
OAAI
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma
2021-03-281
PRE